Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China
Authors' conclusion
The conclusion drawn from this study is that, with insulin glargine as the cost reference, the economic cost of insulin icodec for Chinese type 2 diabetes patients is expected to range from $784.90 to $1145.96, providing a reference basis for clinical decision-making and healthcare policy formulation.
Study context
- Population
- Chinese patients with T2D already receiving basal insulin therapy; data from the ONWARDS 4 trial and Chinese T2D research materials
- Comparison
- Once-weekly insulin icodec vs once-daily insulin glargine
- Outcome
- Rational pricing range of once-weekly insulin icodec
Methodological detailsmodel-based long-term simulation, binary search price analysis, Chinese healthcare system perspective
- Model-based long-term simulation
- Binary search price analysis
- Chinese healthcare system perspective
Main finding
As reported in the abstract
Reasonable cost range of insulin icodec
Reasonable cost range by price sensitivity analysis
$851.95 to $1358.25
Cost range revised after univariate sensitivity analysis; robust in probabilistic sensitivity analysis and scenario simulations
$784.90 to $1145.96
Further findings
QALYs · long-term simulation
Quality-adjusted life years (QALYs) · long-term simulation
- Insulin icodec and insulin glargine performed similarly in QALYs; at an annual cost assumed equal to glargine, icodec may have higher cost-effectiveness potential
Original publication
Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China. Diabetes Obes Metab. Published 30 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →